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The migration of Langerhans cells is an initial event
in the sensitization phase of contact sensitivity.
Langerhans cells travel from the epidermis to the
regional lymph node, and can be variously modulated
in the skin where many cytokines are released from
epidermal cells, dermal cells, T helper (Th) cells, and
other inflammatory cells during the sensitization and
elicitation phase of contact dermatitis, and thus induce
an altered inflammatory skin reaction. The modulatory
effect of the cytokines released in the skin, such as
IL-1b, GM-CSF, and TNF-a as epidermal cytokines,
IL-2, IL-12, and IFN-g as Th1 type cytokines, and IL-4
and IL-10 as Th2 type cytokines, was analyzed using
the chemotactic chamber method in this study.
Both GM-CSF and TNF-a induced the migration
of human Langerhans cells in vitro, whereas IL-1b, IL-2,
IL-10, IL-12, and IFN-g hadno effect onLangerhans cell
migration. In contrast, IL-4 inhibited Langerhans cell
migration in a dose dependent manner. The inhibitory
activity of IL-4 was reversed by both anti-human IL-4
monoclonal antibody and anti-human IL-4 receptor
Langerhans cells represent a distinct type of dendritic cellsthat are known to function as antigen-presenting cells.They bear Fcγ receptors, C3 receptors and Ia antigens(Stingl et al, 1977; Frelinger et al, 1979; Katz et al,1979). They are located in the epidermis and thought
to interact with keratinocytes by the expression of E-cadherin on
their surface (Tang et al, 1993). Downregulation of E-cadherin by
contact allergens may accelerate their migration from the epidermis
to the regional lymph node (LN) in the early phase of contact
sensitivity (Schwarzenberger and Udey, 1996). Antigen-bearing
Langerhans cells migrate a considerable distance to the regional LN
and then function as antigen-presenting cells in contact sensitivity
(Silberberg-Sinakin et al, 1976; Stingl et al, 1978, 1981; Macatonia
et al, 1987; Kripke et al, 1990; Cumberbatch and Kimber, 1990).
Several studies have attempted to elucidate the mechanism of
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monoclonal antibody. IL–4 inhibited the Langerhans
cell migration induced by both TNF-a and GM-CSF.
Furthermore, anti-TNF-RII monoclonal antibody
inhibited both random migration and the migration
induced by TNF-a, but not that induced by GM-CSF.
A reverse-transcriptase-polymerase chain reaction and
fluorescence-activated cell sorter analysis revealed that
TNF-a up-regulated and IL-4 downregulated the TNF
receptor II (TNF-RII) expression of Langerhans cells
at both the mRNA and the protein levels. The pre-
treatment of Langerhans cells with TNF-a enhanced
the migration of Langerhans cells and the expression
of TNF-RII. After pretreating Langerhans cells with
TNF-a, IL-4 inhibited both the migration of
Langerhans cells and the expression of TNF-RII in a
time dependent manner.
These results indicate that IL-4 inhibits the migratory
activity of Langerhans cells by downregulating the
expression of TNF-RII in human Langerhans cells and
thereby modulates the immune response in the skin.
Key words: chemotaxis/contact sensitivity/cytokines/Langer-
hans cell/migration. J Invest Dermatol 113:541–546, 1999
Langerhans cell migration and to define the responsible chemotactic
factor(s) (Cumberbatch and Kimber, 1992; Kaplan et al, 1992;
Halliday and Lucas, 1992; Ma et al, 1994; Kobayashi et al, 1994;
Yamazaki et al, 1996, 1998; Rupec et al, 1996). Accordingly,
antigen-bearing Langerhans cells have been shown to migrate to
the regional LN due to the action of TNF-α and GM-CSF, which
are both derived from epidermal cells. Langerhans cells leave the
epidermal compartment due to the effect of TNF-α, and thereafter
migrate to the dermis and later enter the lymph vessels. TNF-α
has been shown to play a critical role in the Langerhans cell migration
from the epidermis to the lymph nodes in vivo (Cumberbatch and
Kimber, 1990, 1992; Cumberbatch et al, 1994). In line with the
in vivo results, we recently confirmed that TNF-α was essential for
such migration in vitro (Yamazaki et al, 1998). Rupec reported that
a low dose (10–100 U per ml) but not a high dose (1000 U per
ml) of GM-CSF induced the migration of human Langerhans cell,
which is known to be a chemokinetic factor in vitro (Rupec et al,
1996). The cell adhesion molecules contribute to the migration of
Langerhans cells and allow them to reach the regional LN (Tang
et al, 1993). It is still unclear as to whether or not the stimulation
of either TNF-α or GM-CSF sufficiently induces the traveling
process of Langerhans cells. The cytokines that are released and
the cell adhesion molecules that are expressed, either directly or
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indirectly, by application of haptens, in the dermis are thought to
modulate the traveling process of Langerhans cells and modify
the subsequent inflammatory skin reaction (Asada et al, 1997).
Langerhans cells are thus partially modulated by many cytokines
released in the skin, especially those from epidermal cells, dermal
cells, T cells, and other inflammatory cells.
In this study, we attempted to clarify the effect of the Th1-type
and Th2-type cytokines derived from infiltrated T cells on the
migration of human Langerhans cells. A Th2-type cytokine, IL-4,
is known to downregulate Langerhans cell migration induced by
TNF-α and GM-CSF. In addition, the IL-4 induced inhibition of
Langerhans cell migration is closely related to the downregulation of
the expression TNF receptor II (p75, TNF-RII) of Langerhans cells.
MATERIALS AND METHODS
Reagents The following reagents were commercially obtained; Ficoll-
Hypaque solution (density 5 1.070, Lymphoprep) from Nygoard (Oslo,
Norway), Cell Gross-H medium (CGM) from Sumitomo (Tokyo, Japan),
TNF-α, IL-1β, and IFN-γ from R&D Systems (Minneapolis, MN),
GM-CSF, IL-4, IL-10, and IL-12 from Genzyme (Cambridge, MA), IL-2
from Pharmingen (San Diego, CA), CD1a monoclonal antibody (MoAb)
(OKT6) from Orth Diagnostic Systems (NJ), anti-IL-4 MoAb and anti-TNF
receptor II (TNF-RII, p75) from Genzyme (Cambridge, MA), anti-
IL-4R and isotype IgG from Cosmo-bio (Tokyo, Japan), fluorescein
isothiocyanate (FITC)-anti-rat IgG goat F(ab)2 and FITC-anti-mouse IgG
goat F(ab)2 from Leinco (Manchester, St Louis, MO), phycoerythrin (PE)-
labeled anti-CD1a MoAb and the appropriate PE-labeled IgG1 control
MoAb from Pharmingen (San Diego, CA), RAV2 reverse transcriptase
from BRL (Bethesda, MD), NTP from Takara (Tokyo, Japan), and Tag
polymerase from Perkin Elmer Centus (Norfolk, CT).
Preparation of the enriched Langerhans cells Epidermal cells were
prepared from healthy human skin specimens obtained during plastic
surgery after obtaining the patients’ informed consent. Epidermal cells were
dispersed from the epidermis by trypsinization (Foster et al, 1990). After
washing with ‘‘complete medium’’, RPMI 1640 containing 10% heat
inactivated fetal calf serum, 2 mM L-glutamine, 50 mg gentamycin per
ml, 100 U penicillin per ml, 2–8 3 106 epidermal cells were layered on
the top of 4 ml of Ficoll-Hypaque solution and then were centrifuged at
400 3 g for 15 min at room temperature. The cells at the interface were
collected, rinsed twice in complete medium and resuspended in serum-
free CGM. These freshly isolated cells were thereafter used as Langerhans cell
enriched epidermal cells either in the migration assay or the fluorescence-
activated cell sorter (FACS) analysis. The yield of Langerhans cells was
21%–32% in purity and their viability was .90% according to the trypan
blue dye exclusion test.
Langerhans cell migration assay A migration assay was carried out in
a NeuroProbe 48 well micro-chemotaxis chamber as previously described
(Falk et al, 1980; Yamazaki et al, 1996). A sheet of polycarbonate filter
with 8 µm pores (Nucleopore, CA) was placed between the upper and
lower compartment of the chamber. Fifty microliters of Langerhans cell-
enriched epidermal cells, 5–10 3 105 per ml in CGM, were added to the
upper compartment and permitted to migrate through the filter toward
the lower compartment, to which 50 µl of cytokine solution at various
dilutions were added. In some experiments, cytokines were added to both
the upper and the lower compartments. The following cytokines were
added to the chamber: TNF-α (1–1000 ng per ml), GM-CSF (1–1000 U
per ml), and IL-1β (1–100 ng per ml) as epidermal cytokines, IFN-γ (1–
100 U per ml), IL-2 (10–100 U per ml), and IL-12 (10–1000 U per ml)
as Th1 cytokines, and IL-4 (1–10 ng per ml) and IL-10 (10–100 ng per
ml) as Th2 cytokines. After incubation at 37°C for 30–120 min in the
migration chamber in humidified air with 5% CO2, the filter was collected
after wiping off any non-migrating cells and then was fixed in absolute
methanol. The filter was next stained with anti-CD1a MoAb by the ABC
staining method. The number of CD1a-positive cells remaining inside the
pores of the filter but not adhering to the lower surface were counted in
three to five randomly chosen microscopic fields at 2003 magnification.
The mean 1/– SEM of migrated Langerhans cells was calculated based on
the results of three independent experiments.
Modulation of Langerhans cell chemotaxis In order to modulate the
inhibitory activity of IL-4 on Langerhans cell migration, the following
antibodies were added to the upper compartment containing 5 3 105 per
ml Langerhans cell-enriched epidermal cells: anti-IL-4 MoAb (0.1–1.0 µg
per ml), anti-IL-4R MoAb (1–100 µg per ml). The same dose of isotype
IgG (0.1–10 µg per ml) was added to the Langerhans cell-enriched
epidermal cells as a control.
An immunofluorescence (IF) analysis of Langerhans cell-enriched
epidermal cells Langerhans cell-enriched epidermal cells were cultured
for either 90 min, 12 h, or 24 h in complete medium in a 24 well-plate
(Corning, #258201) at 37°C under 5% CO2 in air. After rinsing in ice-
cold phosphate-buffered saline containing 0.1% NaN3 and 1% fetal calf
serum, they were incubated with 10 µg per ml of anti-TNF-RII at 4°C
for 60 min. They were next washed and finally stained with 1 ng per ml
of FITC anti-rat IgG goat F(ab)2 or FITC-anti-mouse IgG goat F(ab)2 at
4°C for 30 min. After a short exposure to normal mouse serum, the cells
were incubated with 2.5 µg per ml of PE-labeled anti-CD1a MoAb or
the appropriate PE-labeled IgG1 control MoAb at 4°C for 60 min. A flow
cytometric analysis was performed by using a FACS Analyzer (Cyto ACE-
150, JASCO, Tokyo, Japan) and 10,000 cells at every injection. All dead
cells were gated out with ethidium bromide.
mRNA expression of Langerhans cells Langerhans cell-enriched
epidermal cells were cultured for either 90 min, 12 h, or 24 h in complete
medium containing 10% fetal calf serum and 1 U per ml of GM-CSF in
the presence or absence of 100 ng per ml TNF-α or IL-4 at 37°C under
5% CO2 in air. After incubating the cells with 10 µg per ml anti-CD1a
MoAb at 4°C for 1 h, they were positively-selected utilizing anti-mouse
IgG-conjugated dynabeads (Dynabeads M-450; Dynal A.S., Oslo, Norway).
The resulting population yielded CD1a1 Langerhans cells with a purify of
more than 95%, which were then used as the purified Langerhans cells in
our experiments. The RNA was extracted from the 106 purified Langerhans
cells as previously described (Yokozeki et al, 1997). The RNA extracted
from the Langerhans cells was reversely transcribed by using 12 U of
RAV2 reverse transcriptase and 20 mg of oligodeoxythymidine primer at
a total volume of 22 µl to amplify the cDNA of TNF-RII by polymerase
chain reaction (PCR). The reaction mixture consisted of 5 µl of cDNA,
5 µl of 103 PCR buffer (500 mM KCl, 100 mM Tris-HCl buffer, pH
8.4, 15 mM MgCl2, and 0.01% gelatin), 4 µl of 2.5 mM NTP, 20.6 µl of
DEPC-water, 2.5 µl of 20 pM 59- and 39-primers and 1.5 U of Tag
polymerase. Amplification was conducted for 30 cycles at 94°C for 1 min,
at 58°C for 2 min, and at 72°C for 3 min for TNF-RII and for 30 cycles
at 94°C for 1 min, at 60°C for 2 min, and 72°C for 1 min for β-actin.
The 59- and 39-primer sequences were as follows: the β-Actin DNA
primers were CCTTCCTGGGCATGGAGTCCTG and GGAGCAA-
TGATCTTGATCTTG (Yokozeki et al, 1997), while the p75 TNF-RII
primers were CTCCAACACGACTTCATCCA and GACACAGTT-
CACCACTCCTA (Hart et al, 1996). The PCR produces were detected
by electrophoresis on 3.0% agarose gel containing ethidium bromide.
IL-4 treatment of TNF-a-pretreated Langerhans cells To determine
the mechanism of inhibitory activity of IL-4 on Langerhans cell migration,
the Langerhans cells were pretreated with 100 ng TNF-α per ml for 12 h,
washed three times with complete medium, and then incubated with 10 ng
IL-4 per ml for either 1.5 h, 3 h, 6 h, 12 h, or 24 h. The migratory
activity of these Langerhans cells was next determined in a chemotactic
chamber and their TNF-RII expression was evaluated by flowcytometry.
Statistical analysis Student’s t-test was used to compare the results. A
p value of less than 0.05 was considered to be significant.
RESULTS
Cytokines modulate the migration of human Langerhans
cells Cells migrating inside the pores in the filter membrane
showed a dendritic shape and expressed CD1a on their surface,
which suggested the migrating cells to be Langerhans cells (data
not shown). We therefore counted the number of CD1a-positive
cells in the pores to assess the degree of Langerhans cell migration.
Next, freshly isolated Langerhans cells were incubated for either
30, 60, 90, or 120 min in a chemotactic chamber. The number of
migrated Langerhans cells reached a peak at 90 min incubation in
the presence or absence of 100 ng TNF-α per ml in the lower
compartment (Fig 1). Incubation for 90 min in the chemotactic
chamber was performed in all further experiments to evaluate the
migration.
In order to determine the effect of cytokines on the migratory
activity of Langerhans cells, a chemotactic assay of the Langerhans
cells was performed by adding either IL-1β, TNF-α, GM-CSF,
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Figure 1. Kinetics of the spontaneous migration and TNF-a induced
migration of isolated human Langerhans cells. Enriched Langerhans
cells were placed in the upper compartment and complete medium (r)
or 100 ng TNF-α per ml (j) in the lower chamber. After incubation for
from 30 to 120 min in the chemotactic chamber, the CD1a positive cells
that moved inside the pores were counted in five high power fields (3200,
HPF). The results are expressed as the mean 6 SEM of the cell number
from three independent experiments.
Figure 2. The effect of cytokines on Langerhans cells migration.
Langerhans cell-enriched epidermal cells (53104 per 50 µl) were placed
in the upper compartment. Varying doses of keratinocyte-derived cytokines,
TNF-α, GM-CSF, and IL-1β, Th1-cytokine, IL-2, IL-12, and IFN-γ, and
Th2-cytokines IL-4, IL-10, were placed in the lower compartment. After
a 90 min incubation period, the filter was stained with anti-CD1a antibody
and then the number of migrating cells was counted in 5 HPF. The results
are expressed as the mean 6 SEM of the cell number from three
independent experiments. *p,0.05 was considered to be significant when
compared with the results obtained with the medium alone.
IFN-γ, IL-2, IL-4, IL-10, or IL-12 to the lower compartment.
TNF-α and GM-CSF enhanced Langerhans cell migration. Ten
to 1000 ng TNF-α per ml and 1–100 U GM-CSF per ml strongly
enhanced Langerhans cell migration; however, 1000 U GM-CSF
per ml inhibited the Langerhans cell migration. IFN-γ, IL-1β, IL-
2, IL-10, and IL-12 had no effect on Langerhans cell migration in
the tested range of cytokine concentration. Interestingly, IL-4
induced a significant inhibition of Langerhans cell migration at a
concentration of 10 ng per ml (p,0.05) (Fig 2).
IL-4 inhibits the migration of Langerhans cells The
Langerhans cells migrated well in the chamber without any cytokine
stimulation possibly due to random migration. As we used Langer-
hans cell-enriched epidermal cells, it is possible that the contamin-
ated epidermal cells released cytokines such as TNF-α and GM-
Figure 3. The effect of IL-4 on the random migration of Langerhans
cells. Five3104 per 50 µl of Langerhans cell-enriched epidermal cells were
placed in the upper compartment. Varying doses of rIL-4 were placed in
the lower compartment. The number of CD1a positive cells in 5 HPF
was counted. The results are expressed as the mean 6 SEM of the cell
number from three independent experiments. *p,0.05.
CSF in the chamber to stimulate the migration. When varying
concentrations of IL-4 (0.1–10 ng per ml) were added to the lower
compartment of the chamber, the migration of Langerhans cells
was inhibited in a dose-dependent manner. Ten nanograms per ml
of IL-4 inhibited the Langerhans cell migration by 82% (Fig 3).
To further examine the role of IL-4, either anti-IL-4 MoAb or
isotype IgG was added to the upper compartment and 10 ng IL-4
per ml to the lower compartment (Fig 4A). The inhibition of
Langerhans cell migration induced by IL-4 was completely reversed
when anti-IL-4 MoAb was added at a concentration as low as 1 µg
per ml. Isotype IgG did not show any activity similar to that
observed by anti-IL-4 MoAb. Anti-IL-4R MoAb was also added
to the upper compartment to see the role of IL-4R in the inhibition
of Langerhans cell migration. IL-4R MoAb also blocked the
inhibition induced by IL-4 (Fig 4B). These data indicate that IL-4
inhibited Langerhans cell migration by binding to the IL-4R
expressed on Langerhans cells.
IL-4 inhibits the Langerhans cell migration induced by both
TNF-a and GM-CSF Because the random migration noted in
this study was possibly induced by the epidermal cytokines released
from contaminated keratinocytes, the effect of IL-4 on the enhanced
migratory activity of Langerhans cells induced by TNF-α and
GM-CSF, was assessed. The combination of 10 ng IL-4 per ml
and 100 ng TNF-α per ml or 1 U GM-CSF per ml was added to
the lower compartment. Ten nanograms IL-4 per ml inhibited the
migration induced by 100 ng TNF-α per ml by 62%, and the
migration induced by 1 U GM-CSF per ml by 43% (Fig 5). These
data suggest that IL-4 inhibits the Langerhans cells migration not
only induced by TNF-α but also that induced by GM-CSF.
Anti-TNF-RII MoAb inhibited the Langerhans cells migra-
tion induced by TNF-a but not GM-CSF Because the TNF-
RII expressed on the surface of Langerhans cells plays a critical
role in Langerhans cell migration (Wang et al, 1997), the effect of
MoAb against TNF-RII on TNF-α or GM-CSF induced
Langerhans cell migration was analyzed. Varying concentrations of
anti-TNF-RII antibody were added to the Langerhans cells in the
upper compartment and 100 ng TNF-α per ml or 1 U GM-CSF
per ml to the lower compartment of the chamber. The addition
of 10 µg TNF-RII MoAb per ml inhibited the TNF-α-induced
chemotactic migration by 80% (Fig 6); however, the GM-CSF-
induced Langerhans cell migration was not affected by TNF-RII
MoAb (Fig 6).
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Figure 4. Blocking by anti- IL-4 MoAb and anti-IL-4R MoAb.
Varying doses of MoAb against IL-4 (A) or IL-4R (B) were added to the
cell suspension (r). A migration assay was performed with IgG1 as a
control antibody (e). The numbers of migrating CD1a-positive cells
significantly increased after the treatment with anti-IL-4 antibody (*p,0.05)
and anti-IL-4 R antibody (*p,0.05) in contrast to the control antibody.
The results are expressed as the mean 6 SEM of the cell number from
three independent experiments.
IL-4 mediated inhibition of Langerhans cell migration
closely paralleled the downregulation of TNF-RII
expression To further analyze the mechanism of IL-4 induced
inhibition of Langerhans cell migration, Langerhans cell enriched
epidermal cells were pretreated with 100 ng TNF-α per ml. After
the Langerhans cell enriched epidermal cells were pretreated for
12 h and washed three times with the medium, they were incubated
in 10 ng IL-4 per ml for either 1.5 h, 3 h, 6 h, 9 h, 12 h, or 24 h
and then were incubated in 6 well culture plates. The enhanced
migration of Langerhans cells by pretreated TNF-α was inhibited
when the Langerhans cells were incubated further with IL-4 for
longer than 6 h. The TNF-RII expression of the treated Langerhans
cells was examined by flow cytometry. The expression of TNF-
RII decreased when the incubation period of IL-4 was prolonged
(Fig 7).
Expression of TNF-RII on Langerhans cells was downregul-
ated by IL-4 As the TNF-RII expression closely paralleled the
IL-4 inhibition of Langerhans cell migration, we analyzed the
modulatory activity of IL-4 on the TNF-RII expression of
Langerhans cells. Purified Langerhans cells, 3 3 105 per ml, were
cultured in 100 ng TNF-α per ml for 90 min, 12 h, or 24 h in
the presence or absence of 10 ng IL-4 per ml. RNA was extracted
from the Langerhans cells and their mRNA expression of TNF-
RII was determined by RT-PCR. The Langerhans cells in an
unstimulated condition did not express TNF-RII mRNA (Fig
8A, lane 2), and the findings were the same for the Langerhans
Figure 5. IL-4 inhibits the Langerhans cell migration induced by
TNF-a and GM-CSF. One hundred nanograms TNF-α per ml or 1 U
GM-CSF per ml were added to 10 ng IL-4 per ml to the lower
compartment. The number of migrating cells decreased when IL-4 was
added. The results are expressed as the mean 6 SEM of the cell number
from three independent experiments. *p,0.05 was considered to be
significant in comparison with the results obtained with TNF-α or GM-
CSF alone.
Figure 6. Anti-TNF-RII MoAb inhibited the Langerhans cell
migration induced by TNF-a but not GM-CSF. 01, 1.0, or 10 ng
anti-TNF-RII MoAb per ml was added to the upper compartment. One
hundred nanograms TNF-α per ml or 1 U GM-CSF per ml was added
to the lower compartment. The number of CD1a-positive cells decreased
in a dose-dependent manner. The results are expressed as the mean 6
SEM of the cell number from three independent experiments. *p,0.05
was considered to be significant when compared with the results obtained
with TNF-α alone.
cells cultured in IL-4 for 12 h (Fig 8A, lane 3). Stimulation with
TNF-α for 12 h upregulated the expression of TNF-RII mRNA
(Fig 8A, lane 4). The expression of TNF-RII mRNA was
completely abolished in Langerhans cells cultured with TNF-α in
the presence of IL-4 (Fig 8A, lane 5 ). The same results were
obtained from the Langerhans cells cultured in TNF-α and IL-4
for 90 min (data not shown). A flow cytometric analysis revealed
that 70.9% of CD1a1 cells cultured in TNF-α for 24 h expressed
TNF-RII, and that number of Langerhans cells expressing TNF-RII
decreased to 47.5% when the CD1a1 Langerhans cells were
cultured in both TNF-α and IL-4 (Fig 8B). The mean fluorescent
intensity (MFI) of TNF-RII was also downregulated to a greater
extent in the CD1a1 Langerhans cells cultured in IL-4 and TNF-
α than when cultured by TNF-α alone (Fig 8B). The experiment
performed with the Langerhans cells cultured for 12 h showed
similar results (data not shown). These data indicate that IL-4
downregulates the expression of TNF-RII at both the mRNA and
the protein levels.
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Figure 7. IL-4 simultaneously inhibited both the migratory activity
and the expression of TNF-RII of Langerhans cells induced by
TNF-a. After the Langerhans cells were cultured with 100 ng TNF-α
per ml for 12 h, the Langerhans cells were harvested and washed. The
Langerhans cells pretreated with TNF-α were then cultured with 10 ng
IL-4 per ml for 1.5 h, 3 h, 6 h, 12 h, or 24 h. A migration assay was
performed on either the medium or TNF-α with these Langerhans cells.
The rate of TNF-RII expression on the Langerhans cell cultured with IL-
4 (d) or without IL-4 (j) was analyzed by FACS. Langerhans cell inhibited
the migratory activity and downregulated the expression rate of TNF-RII
in a time-dependent manner. The results are expressed as the mean 6
SEM of the cell number from three independent experiments. *p,0.05
was considered to be significant when compared with the results obtained
with TNF-α alone.
DISCUSSION
The effect of Th1- or Th2-type cytokines or cytokines derived
from epidermal cells on the migration of human Langerhans cells
was examined in this study by using 48 well micro-chemotaxis
chambers (Yamazaki et al, 1996). In line with the findings of recent
studies (Rupec et al, 1996), both TNF-α and GM-CSF induced
Langerhans cell migration in vitro. In contrast to these cytokines,
IL-4 inhibited the cytokine-induced Langerhans cell migration.
Other cytokines, such as IL-2, IL-10, IL-12, and IFN-γ, did not
affect the migratory activity of Langerhans cells. Langerhans cells
migrated randomly without any exogenous stimulation in this
study. This random migration was also inhibited by IL-4. The
random migration observed in our study may be due to cytokines
released by epidermal cells, because we used Langerhans cell-
enriched epidermal cells in the assay. Contaminating epidermal
cells can release TNF-α and GM-CSF to stimulate Langerhans
cells during the migration assay. Therefore, we carefully analyzed
the mechanism of the IL-4 inhibition of cytokine-induced Langer-
hans cell migration.
Recently, many studies carried out in humans have shown that
the application of epicutaneous sensitizers induced a significant
accumulation of antigen-bearing dendritic cells in the draining
lymph nodes (Cumberbatch et al, 1994). IL-1β is critically involved
in the change of human Langerhans cells induced by contact
allergens in an organ culture system (Rambukkana et al, 1996), and
it also significantly induced Langerhans cell migration from the
epidermis in a similar manner to that caused by contact allergens.
In contrast to their findings, we could not detect any chemotactic
activity of human Langerhans cells by IL-1β in vitro. This discrepancy
may be due to differences in the assay systems used in these
studies. We performed Langerhans cell migration by using
dispersed Langerhans cells, whereas they assessed chemotaxis in
an organ culture system. Kobayashi et al (1994) also demonstrated
that the application of haptens triggered Langerhans cell migration
from the epidermis and suggested that TNF-α produced by
keratinocytes was responsible for this Langerhans cell migration.
Furthermore, Rupec et al (1996) reported that GM-CSF induces
the migration of human Langerhans cells in a chemokinetic
manner. Based on both our observations and the findings of
Figure 8. Expression of p75 TNF-RII was downregulated by IL-4.
The expression of TNF-RII mRNA was detected by RT-PCR after the
purified Langerhans cells were cultured for 12 h in the presence or absence
of 100 ng TNF-α per ml and 10 ng IL-4 per ml (A). Lane 1, molecular
markers; lane 2, medium; lane 3, 10 ng IL-4 per ml; lane 4, 100 ng TNF-
α per ml; lane 5, both 100 ng TNF-α per ml and 10 ng IL-4 per ml. The
mRNA expression of TNF-RII was suppressed by IL-4. The MFI and
the rate of surface expression of TNF-RII was also downregulated by IL-
4 (B). The Langerhans cells cultured for 24 h double-stained with MoAb
against CD1a and TNF-RII. The surface expression of TNF-RII by
100 ng TNF-α per ml alone (B,a) and by 100 ng TNF-α per ml and
10 ng IL-4 per ml (B,b). The results are representative of three independent
experiments.
recent reports, human Langerhans cells are thus considered to
migrate from the epidermis when triggered by either TNF-α
or GM-CSF released from the epidermis at hapten-challenge in
the early phase of contact sensitivity. It is possible that IL-1β
released by hapten application stimulated the release of either
TNF-α or GM-CSF. Such initiated Langerhans cells should be
influenced by the cytokines released in the skin during the
inflammatory process. In line with the findings of a recent
paper, in murine Langerhans cells (Yamazaki et al, 1998), neither
IL-2, IL-10, IL-12, nor IFN-γ derived from infiltrated T cells
in the elicitation phase had the capacity to induce migration of
Langerhans cells from the epidermis. It is noteworthy that IL-4
showed sufficient potency to inhibit the migration of human
Langerhans cells induced by TNF-α and GM-CSF.
In order to clarify the mechanism of the inhibitory activity
of IL-4 on Langerhans cell migration, we attempted to reverse
the inhibitory activity by MoAb against IL-4 and IL-4R. Our
findings revealed that IL-4 inhibited Langerhans cell migration
was reversed by both MoAb against IL-4 and IL-4R; however,
we were not able to eliminate the possibility that the keratinocyte-
derived mediators activated by IL-4 affect the migration of
human Langerhans cells in this study, because human keratinocytes
have IL-4R and express B7/BB1 when stimulated with IL-4
(Junghans et al, 1996; Yang et al, 1996).
It has recently been demonstrated that TNF receptor II plays
a crucial role in the chemotactic migration of murine Langerhans
cells from the epidermis to the lymph nodes (Wang et al, 1997).
Langerhans cell migration is completely blocked in TNF receptor
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II (TNF-RII) deficient mice and the contact sensitivity reaction
was also suppressed in those mice (Wang et al, 1997). On the
other hand, human Langerhans cells express only TNF-RII but
not TNF-RI (Ryffel et al, 1991); however, little is known
regarding the regulatory mechanism of TNF-RII in human
Langerhans cells. Consistent with the data on murine Langerhans
cells, a monoclonal antibody against TNF-RII inhibited the
migration of human Langerhans cells induced by TNF-α, and
the expression of both molecules and the mRNA of TNF-RII
induced by TNF-α was also downregulated by IL-4. Furthermore,
after pretreating the Langerhans cells with TNF-α, IL-4 inhibited
both the migration of Langerhans cells and the expression of
TNF-RII.
These data indicate that IL-4 inhibits the migration of human
Langerhans cells induced by TNF-α by downregulating the
expression of TNF-RII. IL-4 was also reported to suppress the
elicitation phase of contact hypersensitivity (Gautam et al, 1992;
Asada et al, 1997). These authors suggest that IL-4 may blunt
contact sensitivity by regulating the local production of such
proinflammatory cytokines as IL-1β, IFN-γ, and IL-2. While
the precise mechanism for this remains unclear, our data suggest
that the suppression of contact sensitivity induced by IL-4 may
be due to inhibition of Langerhans cell migration.
Although Langerhans cell migration induced by GM-CSF was
not blocked by anti-TNF-RII antibody, IL-4 had an inhibitory
effect on GM-CSF-induced migration. A different mechanism
may thus be involved in the inhibition of GM-CSF-induced
migration by IL-4.
In summary, IL-4 inhibits both the migration of human
Langerhans cells induced by TNF-α through the modulating
expression of TNF-RII and the migration of Langerhans cells
induced by GM-CSF due to some unknown mechanism in this
study. The inhibition of Langerhans cell migration may therefore
modulate the contact sensitivity reaction to various extents.
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